Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 October 2019 | Story Ngang Carol | Photo Stephen Collett
International conference delegates
International delegates attending the International Conference on the Right to Development hosted on the Bloemfontein Campus.

The International Conference on the Right to Development was held in Bloemfontein for the first time from 25 to 27 September 2019, hosted by the Free State Centre for Human Rights at the University of the Free State. This is the third in the international conference series launched in 2017 with the aim of advancing the right to development both in Africa and internationally. This year’s conference follows the previous two that were held at the Centre for Human Rights, University of Pretoria, in September 2017 and August 2018.  

Based on the theme, ‘The right to development and natural resource ownership’, the 3rd International Conference on the Right to Development offered the forum and opportunity to participants from a diversity of backgrounds and disciplines to interact and share knowledge on their research outputs, which extensively explored questions on how natural resource ownership could contribute to the realisation of the right to development. The keynote address was delivered by Prof John C Mubangizi, Dean of the Faculty of Law at the University of the Free State. 

The three-day conference registered a total of 35 participants and 27 presentations out of the 33 that were scheduled. Participants came from different countries, including South Africa, Botswana, Zimbabwe, the Democratic Republic of the Congo, Cameroon, Nigeria, Ghana, Kenya, Uganda, Ethiopia, and the United Kingdom. Some of those who were unable to attend had the opportunity to present their papers through Skype. The presentations stimulated exciting and robust debates. 

The International Conference Series on the Right to Development is jointly organised and co-sponsored by the Centre for Human Rights, University of Pretoria; the Thabo Mbeki African Leadership Institute, University of South Africa; and the Free State Centre for Human Rights, University of the Free Sate. In its three years of existence, it has progressively established a steady track record of publications, including journal articles in special editions of selected journals and collections of chapters in edited volumes. 

The next (fourth) conference is intended to be much bigger and is scheduled to take place in Kigali, Rwanda, in 2021. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept